Rezolute Presents Phase 3 SUNRIZE Data for Hyperinsulinism
Rezolute will deliver an oral presentation of Phase 3 results for ersodetug (sunRIZE; RZ358-301) in congenital hyperinsulinism at the...
AI Drug Discovery AstraZeneca BIO-Europe Spring 2026 biopharma M&A biopharma strategy biotech funding biotech strategy business development cancer immunotherapy China Biotech CNS Pipeline Strategy competitive intelligence Disease-Modifying Therapy Drug Pricing Strategy eClinical Tech News Eli Lilly Emerging Markets FDA Approval FDA Priority Review HER2 Oncology immuno-oncology immunology licensing deals Lifecycle Management Market Access Medtronic MSS colorectal cancer Novo Nordisk Obesity/GLP-1 Obesity Drug Market Obesity Market Oncology Pipeline Patent Cliff Priority Review Voucher pulmonary hypertension Rare Disease Regeneron respiratory biologics Roche Sanofi series A funding Teva Pharmaceuticals Type 1 Diabetes Type 2 Diabetes venture capital
No videos found.
Rezolute will deliver an oral presentation of Phase 3 results for ersodetug (sunRIZE; RZ358-301) in congenital hyperinsulinism at the...
Revolution Medicines will take the ASCO Plenary stage on May 31 to unveil full Phase 3 results from RASolute...
Oculis has completed the final patient visits in both Phase 3 DIAMOND trials of OCS-01, a high-concentration dexamethasone eye...
Atsena Therapeutics has cleared a key gate in its Lighthouse program for X-linked retinoschisis, with an independent data monitoring...
Amneal reported positive interim results from its ongoing Phase 4 ELEVATE-PD switch study, presented at AAN 2026, showing that...
Biogen has acquired TJ Biopharma’s exclusive rights to felzartamab in Greater China for $100 million upfront, up to $750...
The White House has issued an executive order to accelerate development and approval pathways for treatments targeting serious mental...
AB Science has posted a medRxiv preprint reporting a substantial survival signal for masitinib in amyotrophic lateral sclerosis, based...
Rinri Therapeutics has published a comprehensive review framing neural hearing loss—driven by auditory nerve dysfunction—as a central and underdiagnosed...
BVI has secured CE Mark certification under the EU Medical Device Regulation for Virtuoso, a next-generation dual-function surgical platform...
